Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 2 Davis Dr, Durham, NC 27703, USA
- Website
- dignifytherapeutics.com
- Founded
- 2013
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Axonis Therapeutics, Inc. | Boston, MA | — |
| Epigen Biosciences Inc. | San Diego, CA | 325199 All Other Basic Organic Chemical Manufacturing |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Alcamena Stem Cell Therapeutics, LLC | Spencerville, MD | 621511 Medical Laboratories |
| Microcures Inc. | NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Dignify Therapeutics, LLC is a for-profit biotechnology company registered in SAM.gov since 2013, specializing in developing neurological therapies targeting sacral spinal cord neurons and addressing conditions related to bladder, bowel, and sexual function. The company focuses on creating novel drug formulations and therapeutic approaches for patients with neurological conditions, aging-related complications, and specific medical challenges involving continence and functional control.
Through federal grant awards from agencies like the National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute of Diabetes and Digestive and Kidney Diseases, and the Defense Health Agency, Dignify Therapeutics has pursued research and development of innovative treatments for urinary and fecal incontinence, overactive bladder symptoms, and neurological dysfunction. The company's grant-funded projects have included developing drug candidates like DTI-117 for on-demand voiding, creating intravesical and intrarectal drug therapies to block pain-sensing neurons, and researching mechanisms to restore voluntary control of bodily functions for patients with spinal cord injuries, multiple sclerosis, Parkinson's disease, and age-related conditions. Notable collaborations include a sub-grant with Augusta University Research Institute, Inc., and the company has secured multiple project grants totaling several million dollars to advance preclinical research, formulation development, and potential clinical trials for its therapeutic pipeline.
Quick answers
Is Dignify Therapeutics, LLC registered in SAM.gov?
Yes. Dignify Therapeutics, LLC's SAM.gov registration is active through October 14, 2027.
What is Dignify Therapeutics, LLC's CAGE code?
Dignify Therapeutics, LLC's CAGE code is 6XWQ2, and its Unique Entity ID (UEI) is LG53EH7JZLK4.
What is Dignify Therapeutics, LLC's most recent federal award?
Dignify Therapeutics, LLC's most recent federal grant award is Therapy for fecal incontinence and fecalurgency - fecal incontinence and fecal urgency (FI/FU) are extremely… (R43DK138600), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 15, 2024.
On GovTribe
See Dignify Therapeutics, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors